Our prior research has unveiled diminished MT1 expression levels in the SN of PD mouse models, and the activation of MT1 was found to inhibit lipopolysaccharide‐induced microglial activation, influencing their metabolic reprogramming [42]. This evidence concerns the gene MTNR1A and Parkinson disease.